Rallybio Corp: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Rallybio Corp Unternehmen

Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.

Rallybio Corp Informationen



BörsenkürzelRLYB

Name des UnternehmensRallybio Corp

IPO-datumJul 29, 2021

CEODr. Stephen (Steve) Uden, M.D.

Anzahl der mitarbeiter25

WertpapierartOrdinary Share

GeschäftsjahresendeJul 29

Addresse234 Church Street

StadtNEW HAVEN

BörseNASDAQ Global Select Consolidated

LandUnited States of America

Postleitzahl06510

Telefon12038593820

Websitehttps://rallybio.com/

BörsenkürzelRLYB

IPO-datumJul 29, 2021

CEODr. Stephen (Steve) Uden, M.D.

Führungskräfte von Rallybio Corp



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Stephen (Steve) Uden, M.D.

President, Chief Executive Officer, Director

730.36K

+1.56%

Ms. Paula Soteropoulos

Independent Director

23.88K

--

Mr. Jonathan I. (Jon) Lieber

Chief Financial Officer, Treasurer

14.24K

+184.74%

Ms. Helen M. Boudreau

Independent Director

--

Dr. Robert (Rob) Hopfner, Ph.D.

Independent Director

--

Dr. Steven W. Ryder, M.D.

Chief Medical Officer

--

Dr. Wendy K. Chung, M.D., Ph.D.

Independent Director

--

Mr. Ronald M. (Ron) Hunt

Independent Director

--

Dr. Hui Liu, Ph.D.

Independent Director

--

Dr. Lucian Iancovici, M.D.

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Stephen (Steve) Uden, M.D.

President, Chief Executive Officer, Director

730.36K

+1.56%

Ms. Paula Soteropoulos

Independent Director

23.88K

--

Mr. Jonathan I. (Jon) Lieber

Chief Financial Officer, Treasurer

14.24K

+184.74%

Ms. Helen M. Boudreau

Independent Director

--

Dr. Robert (Rob) Hopfner, Ph.D.

Independent Director

--

Dr. Steven W. Ryder, M.D.

Chief Medical Officer

--

Umsatzaufteilung

FY2024

Keine Daten

Nach RegionUSD

Name

Umsatz

Anteil

United States

636.00K

0.00%

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Fri, Aug 15

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Viking Global Investors LP

10.04%

Johnson & Johnson Innovation-JJDC, Inc.

8.70%

5AM Ventures

8.69%

New Leaf Venture Partners LLC

7.90%

TPG Capital, L.P.

7.25%

Andere

57.42%

Aktionäre

Anteil

Viking Global Investors LP

10.04%

Johnson & Johnson Innovation-JJDC, Inc.

8.70%

5AM Ventures

8.69%

New Leaf Venture Partners LLC

7.90%

TPG Capital, L.P.

7.25%

Andere

57.42%

Aktionärstypen

Aktionäre

Anteil

Venture Capital

34.06%

Investment Advisor/Hedge Fund

14.95%

Investment Advisor

12.87%

Private Equity

7.25%

Individual Investor

4.14%

Hedge Fund

3.93%

Research Firm

0.38%

Pension Fund

0.03%

Andere

22.38%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

137

30.70M

73.47%

-4.83M

2025Q2

146

33.40M

80.25%

-5.22M

2025Q1

153

34.13M

82.02%

-4.90M

2024Q4

156

33.77M

81.40%

-4.07M

2024Q3

163

33.31M

80.30%

-4.27M

2024Q2

165

34.52M

83.29%

-5.35M

2024Q1

149

33.11M

86.93%

-2.72M

2023Q4

143

34.47M

90.96%

-619.59K

2023Q3

138

35.89M

94.72%

-1.76M

2023Q2

134

36.21M

95.77%

-44.55K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Viking Global Investors LP

4.19M

10.04%

--

Jun 30, 2025

Johnson & Johnson Innovation-JJDC, Inc.

3.64M

8.7%

--

Jun 30, 2025

5AM Ventures

3.63M

8.69%

--

Jun 30, 2025

New Leaf Venture Partners LLC

3.30M

7.9%

--

Jun 30, 2025

TPG Capital, L.P.

3.03M

7.25%

--

Jun 30, 2025

Pivotal Bioventure Partners Investment Advisor LLC

2.40M

5.75%

--

Jun 30, 2025

Fidelity Management & Research Company LLC

1.87M

4.48%

+85.06K

+4.76%

Jun 30, 2025

Almitas Capital LLC

1.82M

4.35%

+516.91K

+39.74%

Jun 30, 2025

abrdn Inc.

1.60M

3.82%

-131.81K

-7.63%

Jun 30, 2025

The Vanguard Group, Inc.

909.94K

2.18%

-61.99K

-6.38%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Sun, Nov 2

Name

Anteil

Global X Russell 2000 ETF

0%

Avantis US Small Cap Equity ETF

0%

ProShares UltraPro Russell2000

0%

ProShares Hedge Replication ETF

0%

iShares Russell 2000 Value ETF

0%

Proshares Ultra Russell 2000

0%

iShares Micro-Cap ETF

0%

Global X Russell 2000 Covered Call ETF

0%

iShares Russell 2000 ETF

0%

Global X Russell 2000 ETF

Anteil0%

Avantis US Small Cap Equity ETF

Anteil0%

ProShares UltraPro Russell2000

Anteil0%

ProShares Hedge Replication ETF

Anteil0%

iShares Russell 2000 Value ETF

Anteil0%

Proshares Ultra Russell 2000

Anteil0%

iShares Micro-Cap ETF

Anteil0%

Global X Russell 2000 Covered Call ETF

Anteil0%

iShares Russell 2000 ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten